Market Research Logo

RNA Therapeutics

RNA Therapeutics

SMi Group announces the return of its 8th annual RNA Therapeutics conference to London on the 22nd - 23rd of February 2017. Technology in RNA interference, oligonucleotides and mRNA has revolutionised the way infectious disease, cancer and neurological disorders are treated. It is now possible to target previously ‘un-druggable’ sites, therefore expanding the range of therapeutics that selectively silence genes before the disease develops.


AstraZeneca has added another $140 million to its $1.2 billion investment into Moderna Therapeutics’ mRNA technology*. Consequently continued collaboration between pharmaceutical giants and innovative biotechnology companies, has created considerable funding and buzz around RNA research.

The main challenge in RNA therapeutics continues to be the delivery of RNA based drugs to target sites outside the liver. Join us in exploring the different delivery systems in use and in development such as transportation with nanoparticles and the ability to enhance drug stability.

We will be reviewing clinical trial updates in RNA- based therapeutics and discussing the current regulations involved in getting drug approval. Learn about the main developments currently shaping the industry and how best to tackle challenges facing RNA therapeutics.


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
9:10
RNA activation and its clinical application
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
9:50
Collaborating to deliver macromolecules across biological barriers – a review of IMI COMPACT
Steve Hood, Director, Scinovo, GSK
10:30
Morning Coffee
11:00
Delivery of mRNA using the Viromer® system
Steffen Panzner, Managing Director, Lipocalyx
11:40
Therapeutic antisense oligonucleotides in oncology
Mark Edbrooke, Senior Principal Scientist, AstraZeneca
12:20
Networking Lunch
13:30
RNA Therapeutics Harnessing the Potential of Locked
Bo Rode Hansen, Director, Technology and Partnered Discovery, Santaris Pharma A/S
14:10
Sites of RNA silencing: Cell entry of exosomes as a novel paradigm for therapeutic RNA delivery
Nicole meisner-kober, Senior Investigator, Novartis Institutes for Biomedical Research
14:50
Afternoon Tea
15:20
RNAi and tumor microenvironment: pre-clinical and clinical evidence
Amotz Shemi, CEO, Silenseed
16:00
Individualized mRNA-based cancer immunotherapy
Andreas Kuhn, Vice President RNA Biochemistry & Manufacturing, BioNTech
16:40
Chairman’s Closing Remarks and Close of Day One
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
9:10
Antisense in the fourth decade: Third generation antisense (3GA) fulfi lling the promise
Sudhir Agrawal, President & C S O, Idera Pharmaceuticals
9:50
Interacting with the medicines regulator on RNAi therapies
John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
10:30
Morning Coffee
11:00
Nano-therapeutics; the best of all possible worlds?
Andrew Miller, CSO, KP Therapeutics Ltd
11:40
Protecting your innovative products and methods: How to patent RNA therapeutics
Mark Chapman, Partner, Carpmaels & Ransford
12:20
Networking Lunch
13:30
Intravenously injectable RNA Nanomedicines as cancer vaccines: case study with RNA-Lipoplexes
Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG
14:10
The challenges and lessons learnt about the delivery of small and large nucleic acids to cancers
Sanyogitta Puri, Associate Prinicipal Scientist, AstraZeneca
14:50
Afternoon Tea
15:20
Protecting the kidney: using siRNA targeting p53 to prevent and ameliorate acute kidney injury and delayed graft functio
Shai Erlich, VP, Pharmaceutical Development, Quark Biotech Inc
16:00
Spherical Nucleic Acids:Structures for topical gene regulation
David Giljohann, CEO, Exicure Inc.
17:00
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report